Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Multi-center Study of AL101 in Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations

NCT03691207 is registered in ClinicalTrials.gov with Ayala Pharmaceuticals, Inc, as lead sponsor.

NCT NCT03691207
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03691207 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Multi-center Study of AL101 in Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations
Lead sponsor
Ayala Pharmaceuticals, Inc,
Phase
Phase 2
Overall status
Completed
Start date
December 14, 2018
Completion date
December 2, 2022
Enrollment
87 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

adenoid cystic carcinoma